Tarsus Pharmaceuticals announces results from Carpo, phase 2a trial of TP-05

Tarsus Pharmaceuticals announced positive topline results from the Phase 2a Carpo trial evaluating TP-05, a novel, investigational oral therapeutic for the prevention of Lyme disease. In this randomized, double-blind, placebo-controlled trial, the ability of TP-05 to kill ticks attached to subjects with a single treatment of TP-05 was evaluated compared to placebo. Both the high and low doses of TP-05 demonstrated a statistically significant benefit in killing ticks compared to placebo. Specifically, after the Day 1 tick challenge, mean tick mortality was 97.0% and 92.0% for the high and low doses of TP-05, respectively, compared to only 5.0% for placebo. Similarly, at the 30-day challenge, mean tick mortality at 24 hours after placement was 89.0% and 91.0% for the high and low doses of TP-05, respectively, compared to only 9.0% for placebo. No statistically significant differences in tick mortality were observed between the two TP-05 treatment arms, and TP-05 was generally well tolerated.